Tag: MD2

Poster-Disease-modifying Therapy

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...

Read More

Poster-Case Reports / Case Series

Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder

Background:: Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. By preventing the cleavage of C5...

Read More

Poster-Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More

Platform-Rehabilitation

Spasticity Experience in Adults with Multiple Sclerosis: An Integrated Conceptual Model

Background: Spasticity is a common symptom of multiple sclerosis (MS), often leading to functional limitations and disability. Objectives:...

Read More

Platform-Neuroimaging

Accurate Cervical Spinal Cord Area Measurements Can be Extracted from Brain Images

Background: Multiple Sclerosis (MS) is an inflammatory, demyelinating disease with neurodegeneration in the central nervous system. Spinal...

Read More

Platform-Disease Management

Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial

Background: Black, African American (AA) and Hispanic/Latino (HA) patients with multiple sclerosis (MS) have greater disease severity and...

Read More

Platform-Rehabilitation

Effects of weekly participation in a wellness program on people living with multiple sclerosis: a three-year analysis

Background: The Multiple Sclerosis Achievement Center (MSAC) conducts day wellness programs to address physical, cognitive and social...

Read More

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More